Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study

Overview of attention for article published in BMC Pulmonary Medicine, February 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#15 of 2,021)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 12 news outlets

twitter: 18 X users

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 17 news stories from 12 outlets.

Teva Announces New Findings Highlighting Potential of ProAir(TM) Digihaler(TM) (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

Stockwatch, 17 May 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new study…

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

Crwe World, 17 May 2022

11:45 UTC Results were presented in a late-breaking oral session at the ATS 2022 annual meeting TEL AVIV, Israel

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

The Daily Times, 17 May 2022

- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

Bakersfield, 17 May 2022

- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 13 additional news stories.